Polymyxin B
| Evidence Level: L1 | Predicted Indications: 3 |
Table of Contents
Polymyxin B: From Gram-Negative Bacterial Infections to Bacterial Conjunctivitis
One-Sentence Summary
Polymyxin B is a polypeptide antibiotic historically used against serious systemic infections caused by gram-negative bacteria (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii). The TxGNN model predicts it may also be effective for Bacterial Conjunctivitis, with 3 clinical trials and 20 publications currently supporting this direction — the strongest-evidence candidate among three predicted indications in this evidence pack (bronchitis and laryngotracheitis are also flagged, with substantially weaker evidence; see “Additional Predicted Indications” below).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in this evidence pack ([Data Gap] flagged — DG002). Polymyxin B is a well-known polypeptide antibiotic used for serious systemic gram-negative infections. |
| Predicted New Indication | Bacterial Conjunctivitis |
| TxGNN Prediction Score | 99.06% (rank 13,826) |
| Evidence Level | L1 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data for Polymyxin B is not available in this evidence pack (data gap DG002, severity High). Based on known pharmacology, Polymyxin B belongs to the polymyxin class of antibiotics; its bactericidal activity against gram-negative organisms is well established, and mechanistically it may be applicable to bacterial conjunctivitis.
Polymyxin B binds to lipopolysaccharide (LPS) on the outer membrane of gram-negative bacteria, disrupting membrane integrity and killing organisms such as Pseudomonas and Haemophilus species that commonly cause bacterial conjunctivitis. This is not a purely speculative repurposing signal — a fixed-dose combination, Polymyxin B/Trimethoprim (brand name Polytrim), is already approved and marketed in multiple countries specifically for bacterial conjunctivitis, and the mechanism is directly consistent with its established antibacterial use.
The relationship between the drug’s known systemic/topical antibacterial use and the predicted ocular indication is therefore mechanistically coherent: both target the same class of gram-negative pathogens, and topical ophthalmic use simply narrows the route of administration and target tissue rather than introducing a novel mechanism.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00581542 | Phase 4 | Completed | 124 | Single-blinded trial comparing Polytrim (polymyxin B/trimethoprim) ophthalmic solution vs. moxifloxacin ophthalmic solution for pediatric conjunctivitis; direct head-to-head efficacy comparison. |
| NCT01227863 | Phase 3 | Unknown (completion not confirmed) | 70 | Compared two branded dexamethasone+neomycin+polymyxin B combination products (Maxinom vs. Maxitrol) for acute bacterial conjunctivitis; efficacy contribution not isolated to polymyxin B alone. |
| NCT01809483 | Phase 3 | Completed | 32 | Compared bandage contact lens vs. pressure patching for corneal erosion healing/pain; polymyxin B not the primary study intervention — indirectly relevant only. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 19043943 | 2008 | RCT | J Pediatr Ophthalmol Strabismus | Moxifloxacin vs. polymyxin B/trimethoprim in pediatric bacterial conjunctivitis. |
| 23092529 | 2013 | RCT | J Pediatr | Single-blinded RCT: polymyxin B-trimethoprim vs. moxifloxacin for acute conjunctivitis in children. |
| 19043945 | 2008 | RCT | J Pediatr Ophthalmol Strabismus | Multicenter comparison of speed of clinical efficacy: polymyxin B/trimethoprim vs. moxifloxacin for bacterial conjunctivitis. |
| 6188739 | 1983 | RCT | J Antimicrob Chemother | Multicentre trial: trimethoprim-polymyxin B vs. neomycin-polymyxin B-gramicidin and chloramphenicol for presumptive bacterial conjunctivitis. |
| 2370842 | 1990 | RCT | Med Lett Drugs Ther | Trimethoprim-polymyxin B for bacterial conjunctivitis — efficacy summary. |
| 2850891 | 1988 | RCT | Curr Med Res Opin | Double-blind trial: trimethoprim-polymyxin B vs. chloramphenicol ophthalmic ointment; comparable efficacy, no significant difference. |
| 2540136 | 1989 | RCT (pooled review) | J Antimicrob Chemother | Review of four RCTs (528 patients): trimethoprim-polymyxin B vs. chloramphenicol ointment for bacterial conjunctivitis. |
| 8595639 | 1995 | Cohort | Clin Ther | Survey of children with acute bacterial conjunctivitis treated with trimethoprim-polymyxin B ophthalmic solution. |
| 11270936 | 2001 | Review | Drugs | Comparative review of topical ophthalmic antibacterials; notes polymyxin B’s gram-negative-selective spectrum. |
| 14686993 | 2003 | Case Report | Clin Microbiol Infect | Primary meningococcal conjunctivitis successfully treated with topical polymyxin B/neomycin/gramicidin followed by systemic rifampin. |
India Market Information
Polymyxin B currently has no marketing authorizations recorded for India in this evidence pack (0 registrations, market status: not marketed). No India-specific product, dosage form, or approved-indication data is available.
Additional Predicted Indications (Exploratory, Lower Evidence)
Two other candidate indications appear in this evidence pack with substantially weaker support and are not the recommended focus at this time:
| Indication | TxGNN Score | Evidence Level | Trials / Literature | Recommendation |
|---|---|---|---|---|
| Bronchitis | 99.87% (rank 2,991) | L4 | 0 trials / 14 publications, mostly 1970s–1980s inhalation-provocation and animal/case-series studies on airway hyperreactivity, not therapeutic efficacy | Research Question — mechanistically plausible for gram-negative tracheobronchitis, but current literature is largely non-therapeutic (bronchial provocation testing) rather than treatment evidence |
| Laryngotracheitis | 99.62% (rank 6,961) | L5 | 0 trials / 0 publications | Hold — model prediction only, no supporting clinical or literature evidence |
Safety Considerations
Drug Interactions: A completed DDI query identified 73 total interactions. Notable Major-level interactions include neuromuscular blockers/paralytics (e.g., Cisatracurium), other nephrotoxic/ototoxic agents (e.g., Amikacin, Cidofovir), radiocontrast agents (Iothalamic acid, Diatrizoate), immunoglobulin products, and botulinum toxin products — consistent with polymyxin B’s known potential to potentiate neuromuscular blockade and nephrotoxicity. Moderate-level interactions include estrogens (Ethinylestradiol, Estradiol, Mestranol) and several other agents.
Detailed key warnings and contraindications from local product labeling are not yet available in this dataset (flagged as a blocking data gap, DG001 — pending retrieval of the labeling document). Please refer to the package insert once available for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The bacterial conjunctivitis indication is supported by an L1 evidence base, including a completed Phase 4 head-to-head RCT and multiple additional RCTs, and is consistent with an already-marketed combination product (Polymyxin B/Trimethoprim) used for this indication elsewhere. However, Polymyxin B is not currently registered in India, and formal labeling (warnings/contraindications) is still a blocking data gap.
To proceed, the following is needed:
- TFDA/CDSCO-equivalent product labeling (warnings, contraindications) — currently a blocking data gap (DG001)
- Formal DrugBank mechanism-of-action data (DG002)
- Assessment of route/formulation compatibility for an India-market ophthalmic product (no current registrations)
- If pursuing bronchitis further: prospective therapeutic (not provocation-model) studies, as current literature does not demonstrate treatment efficacy
- Laryngotracheitis is not recommended for further investment absent new clinical or literature evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.